Humanigen Inc (HGENQ)

[DonDonDonDon]

VERU is up about 200% on a very questionable trial of only 150 patients. Placebo had a mortality rate of 45% which makes no sense. If VERU can go up 200% on trial results that have virtually no chance at getting an EUA then HGEN might go up 2,000% if/when it gets stat sig for a second time.

The primary endpoint population of the ACTIV trial are patients with a CRP<150mg/L + <85yo + on remdesivir. That population had 243% efficacy in the LIVE-AIR trial on the primary endpoint. Stat sig in the ACTIV trial is a given on the primary endpoint. Stat sig on mortality is a real possibility. The LIVE-AIR had stat sig on mortality with the 336 patients with CRP<150mg/L and <85yo. There is still no effective treatment for newly hospitalized patients. Lenzilumab is a game-changer. Data will be our savior.